In vitro enzymatic activity of human immunodeficiency virus type 1 reverse transcriptase mutants in the highly conserved YMDD amino acid motif correlates with the infectious potential of the proviral genome.
about
Posttranslational acetylation of the human immunodeficiency virus type 1 integrase carboxyl-terminal domain is dispensable for viral replicationLocalization of human intestinal defensin 5 in Paneth cell granulesHigh-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptaseInhibition of human immunodeficiency virus type 1 reverse transcriptase by the 5'-triphosphate beta enantiomers of cytidine analogsRapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptasePatterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor lovirideMutational sensitivity patterns define critical residues in the palm subdomain of the reverse transcriptase of human immunodeficiency virus type 1.HIV-1 Transmission, Replication Fitness and Disease Progression.Development of an in vivo assay to identify structural determinants in murine leukemia virus reverse transcriptase important for fidelityYADD mutants of human immunodeficiency virus type 1 and Moloney murine leukemia virus reverse transcriptase are resistant to lamivudine triphosphate (3TCTP) in vitro.Novel lentiviral vectors with mutated reverse transcriptase for mRNA delivery of TALE nucleasesSubunit-specific analysis of the human immunodeficiency virus type 1 reverse transcriptase in vivo.Higher fidelity of RNA-dependent DNA mispair extension by M184V drug-resistant than wild-type reverse transcriptase of human immunodeficiency virus type 1.Antiretroviral Therapy for HIV-2 Infection: Recommendations for Management in Low-Resource SettingsAnalysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1.Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcriptionMutations at codon 184 in simian immunodeficiency virus reverse transcriptase confer resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidineInteraction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1.Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase.Endogenous reverse transcription assays reveal high-level resistance to the triphosphate of (-)2'-dideoxy-3'-thiacytidine by mutated M184V human immunodeficiency virus type 1Nucleotide substitutions within U5 are critical for efficient reverse transcription of human immunodeficiency virus type 1 with a primer binding site complementary to tRNA(His)Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.Minimal sequence requirements of a functional human immunodeficiency virus type 1 primer binding site.Mutational analysis of the conserved motifs of influenza A virus polymerase basic protein 1Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biologyEnzymatic activity of poliovirus RNA polymerases with mutations at the tyrosine residue of the conserved YGDD motif: isolation and characterization of polioviruses containing RNA polymerases with FGDD and MGDD sequencesMechanism of inhibition of human immunodeficiency virus type 1 reverse transcriptase by a stavudine analogue, 4'-ethynyl stavudine triphosphateRelative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20).Second-site reversion of a human immunodeficiency virus type 1 reverse transcriptase mutant that restores enzyme function and replication capacity.The M184V substitution in human immunodeficiency virus type 1 reverse transcriptase delays the development of resistance to amprenavir and efavirenz in subtype B and C clinical isolates.Limiting deoxynucleoside triphosphate concentrations emphasize the processivity defect of lamivudine-resistant variants of human immunodeficiency virus type 1 reverse transcriptaseAn aspartic acid at amino acid 108 is required to rescue infectious virus after transfection of a poliovirus cDNA containing a CGDD but not SGDD amino acid motif in 3DpolInitial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptaseFusion to Flaviviral Leader Peptide Targets HIV-1 Reverse Transcriptase for Secretion and Reduces Its Enzymatic Activity and Ability to Induce Oxidative Stress but Has No Major Effects on Its Immunogenic Performance in DNA-Immunized Mice.Conformational dependence of 13C shielding and coupling constants for methionine methyl groups.The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations.Codon optimization and improved delivery/immunization regimen enhance the immune response against wild-type and drug-resistant HIV-1 reverse transcriptase, preserving its Th2-polarity.
P2860
Q24672416-ED4804A6-B1D3-42A1-8FEA-8B6FCA6F9DD9Q24674859-F4E1E4D3-C380-4752-8F4F-3E7420B4A920Q28367493-7D9EC236-F7E8-49C0-B2E9-1C3A14774705Q28367642-CF8A5628-19AF-4473-9A46-EBCBDE546EF5Q28368030-873EA849-9C87-405A-A95C-4E227292DA22Q28369293-DEADBBCF-DE5F-4767-8369-F56EBCFED3FCQ30416860-641619E2-AA6A-4884-B6E1-C58FA5D64AC8Q33758570-7C37B06A-B019-4946-9BEC-504EE5D8FEE9Q33794922-D4526E67-E79F-4E32-A227-8C74D3334E75Q33842803-561E833E-F3E2-49BE-8B86-F31D403F5226Q34200828-18BBBFEE-4144-46BA-8039-4176FE98E5D9Q34438247-72B43A3D-5A78-4838-BA6B-A7C8CBF53BC4Q34644794-E134DFE0-8532-44BC-A5B2-D6B889588AA4Q34730950-3AFCC5CF-C60F-4327-89D2-15ABD6675DE3Q35116619-817FECC0-68E2-4A97-A5E0-77F8E5FD69BDQ35122784-71881B24-44F7-47BE-B667-AE60240B926BQ35139503-58911599-68B6-44CE-BA17-D9FF5ED226EFQ35363594-D751D10B-C67D-47D2-BAF3-4A3857C76663Q35566910-46D658D1-6878-4E9D-9317-D13CABAD43C1Q35866621-6A4BFA22-8D68-4FBC-A5C2-6AAB293616BAQ35890905-BF084692-2205-49DF-94FA-F3125F1BFD29Q35905947-FE7FAAD2-7975-4D00-991C-3B6A69F5E35DQ36629265-2E153C6A-72F7-4528-B159-C62AC6935B41Q36630055-4E92E995-DA65-4EA0-957B-0BC2438A71ECQ36637244-EA480963-3842-4425-9D3E-799EC7DDDC26Q36639608-BCB91B5E-C713-4515-BC8A-F5F5B618DE6EQ36703003-84BF8CB9-6703-424C-9E8C-82940C2467DCQ37422462-8A2CEF40-6479-4BBF-AB0C-516EEBB86BFDQ39595110-B8B545CB-D18C-42CF-94D8-702ABA9B0A97Q39776171-855EFB30-EB6C-4CAA-A257-4D8AED28F987Q39785298-ED3A9BB5-AF0A-45B8-A1E4-FAB56A5AEB30Q39872900-050F8231-80E0-4076-B590-3C1384E64176Q39879230-7F600A86-609E-45AD-B516-BC2F304E667CQ40119086-1F25C1CD-1BE6-4A18-B28C-2CD4CE9FB134Q41080363-A7AB58D4-CF00-47E6-9725-E1204652A01DQ42117884-85FD86E9-4C86-4976-9D8F-392F063B7DA1Q55154648-5E124EEE-C9D6-4FCC-84C6-C02F9CC9FA04
P2860
In vitro enzymatic activity of human immunodeficiency virus type 1 reverse transcriptase mutants in the highly conserved YMDD amino acid motif correlates with the infectious potential of the proviral genome.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
In vitro enzymatic activity of ...... ential of the proviral genome.
@ast
In vitro enzymatic activity of ...... ential of the proviral genome.
@en
type
label
In vitro enzymatic activity of ...... ential of the proviral genome.
@ast
In vitro enzymatic activity of ...... ential of the proviral genome.
@en
prefLabel
In vitro enzymatic activity of ...... ential of the proviral genome.
@ast
In vitro enzymatic activity of ...... ential of the proviral genome.
@en
P2093
P2860
P1433
P1476
In vitro enzymatic activity of ...... ential of the proviral genome.
@en
P2093
C D Morrow
J K Wakefield
S A Jablonski
P2860
P304
P407
P577
1992-11-01T00:00:00Z